Evidence map›Paper›PMID 40796679›Full record

ArticleBreast cancer research and treatment2025

Worse prognosis for breast cancer diagnosed in advanced pregnancy and shortly postpartum: an update of the Dutch pregnancy-associated breast cancer cohort.

Carsten F J Bakhuis, Stefan Preković, Britt B M Suelmann, Janneke Verloop, Pieter J Westenend, Sabine C Linn, Paul J van Diest, Elsken van der Wall, Carmen van Dooijeweert

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Carsten F J BakhuisDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-2344-9252
Stefan PrekovićCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-7051-9321
Britt B M SuelmannDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-7155-3337
Janneke VerloopNetherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.ORCID http://orcid.org/0009-0005-8910-327X
Pieter J WestenendPALDordrecht, Dordrecht, The Netherlands.ORCID http://orcid.org/0000-0002-5509-920X
Sabine C LinnDepartment of Medical Oncology, Netherlands Cancer Institute (NKI/AvL), Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-5541-0347
Paul J van DiestDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. p.j.vandiest@umcutrecht.nl.ORCID http://orcid.org/0000-0003-0658-2745
Elsken van der WallDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-2568-6937
Carmen van DooijeweertDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-8030-4335

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBreast cancer diagnosed during pregnancy (PrBC) or postpartum (PPBC) is associated with a poorer prognosis, and earlier research indicated that outcomes differ based on timing of diagnosis. We updated and expanded our Dutch nationwide pregnancy-associated breast cancer (PABC) cohort, now also including patients diagnosed within one year after an interrupted pregnancy (AABC), to compare disease characteristics and prognosis across PrBC-, PPBC- and AABC subgroups and to non-PABC patients.

methodsAll breast cancer pathology reports of women < 45 years in the Netherlands (1988-2022) were screened to identify patients diagnosed with PrBC, PPBC (< 12 months postpartum) or AABC (< 12 months after pregnancy interruption). PABC patients were 1:3 matched on age and year of diagnosis to non-PABC breast cancer patients.

resultsIn our PABC cohort (N = 787), the majority was diagnosed during pregnancy (n = 471, 60%). Two distinct prognostic subgroups were observed: a favorable group including trimester 1 PrBC, PPBC 6-12 months postpartum and AABC, and an unfavorable group diagnosed later in pregnancy (trimesters 2 and 3) or shortly postpartum (< 6 months). PABC patients showed overall, in comparison to non-PABC controls, poorer histopathological characteristics (more grade III and triple negative tumors) and a significantly worse 5-year overall survival (77% vs. 85%), persisting in multivariable analysis (HR 1.6, 95% CI 1.06 - 2.33, P = 0.025).

conclusionsPABC patients diagnosed in advanced pregnancy or shortly postpartum are most at risk for aggressive histopathology and an unfavorable prognosis. This highlights the need for in-depth analyses between specific PABC subgroups to elucidate the etiologic mechanisms involved.

Indexed as

Breast NeoplasmsPregnancy Complications, NeoplasticAdultCohort StudiesFemaleHumansMiddle AgedNeoplasm StagingNetherlandsPostpartum PeriodPregnancyPrognosisBreast cancerMiscarriagePostpartumPregnancyPrognosis

Identifiers

PMID40796679
PMCPMC12464139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.